Quarterly report pursuant to Section 13 or 15(d)

Consolidated Balance Sheets (Unaudited)

v3.24.2.u1
Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents [note 6] $ 14,756 $ 15,546
Short-term investments [note 6] 46,557  
Grant receivable [note 3]   111
Prepaid expenses and other assets 1,206 1,325
Total current assets 62,519 16,982
Right-of-use assets [note 9] 35 66
Other assets and restricted cash [note 6] 117 92
License agreement [note 4 and note 5] 1,086 1,197
Goodwill 1,034 1,034
Total assets 64,791 19,371
Current liabilities:    
Accounts payable 550 618
Accrued liabilities other 617 351
Contingent consideration [note 5 and note 6] 637 528
Accrued clinical liabilities 1,708 280
Accrued compensation 1,349 2,311
Current portion of long-term obligations [note 9] 37 63
Current portion of convertible debt [note 6 and note 7] 8,804 16,662
Total current liabilities 13,702 20,813
Non-current portion of convertible debt [note 6 and note 7] 8,804  
Long-term obligations [note 9]   6
Total liabilities 22,506 20,819
Commitments and contingencies [note 9]
Stockholders' equity:    
Common stock, $0.001 par value, 150,000,000 shares authorized, 34,341,303 issued and outstanding at June 30, 2024 and 21,165,760 issued and outstanding at December 31, 2023 103 90
Additional paid-in capital 222,895 164,209
Accumulated deficit (180,706) (165,751)
Accumulated other comprehensive income (7) 4
Total stockholders' equity 42,285 (1,448)
Total liabilities and stockholders' equity 64,791 19,371
Series A Convertible Preferred Stock [Member]    
Stockholders' equity:    
Convertible preferred stock, value
Series B Convertible Preferred Stock [Member]    
Stockholders' equity:    
Convertible preferred stock, value